The relationship between antihypertensive medications and mood disorders: analysis of linked healthcare data for 1.8 million patients

Abstract

Background Recent work suggests that antihypertensive medications may be useful as repurposed treatments for mood disorders. Using large-scale linked healthcare data we investigated whether certain classes of antihypertensive, such as angiotensin antagonists (AAs) and calcium channel blockers, were associated with reduced risk of new-onset major depressive disorder (MDD) or bipolar disorder (BD). Method Two cohorts of patients treated with antihypertensives were identified from Scottish prescribing (2009–2016) and hospital admission (1981–2016) records. Eligibility for cohort membership was determined by a receipt of a minimum of four prescriptions for antihypertensives within a 12-month window. One treatment cohort (n = 538 730) included patients with no previous history of mood disorder, whereas the other (n = 262 278) included those who did. Both cohorts were matched by age, sex and area deprivation to untreated comparators. Associations between antihypertensive treatment and new-onset MDD or bipolar episodes were investigated using Cox regression. Results For patients without a history of mood disorder, antihypertensives were associated with increased risk of new-onset MDD. For AA monotherapy, the hazard ratio (HR) for new-onset MDD was 1.17 (95% CI 1.04–1.31). Beta blockers' association was stronger (HR 2.68; 95% CI 2.45–2.92), possibly indicating pre-existing anxiety. Some classes of antihypertensive were associated with protection against BD, particularly AAs (HR 0.46; 95% CI 0.30–0.70). For patients with a past history of mood disorders, all classes of antihypertensives were associated with increased risk of future episodes of MDD. Conclusions There was no evidence that antihypertensive medications prevented new episodes of MDD but AAs may represent a novel treatment avenue for BD.

Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives

“…However, experimental data suggest that RAS inhibitors may have mood-elevating effects (111). Also, some (112)(113)(114), but not all (115,116), explorative observational studies have suggested that RAS inhibitors may protect against depression.…”

Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes

“…In a Scottish hospital database, the lowest risks of admission for depressive illness over a 5-year period occurred in patients treated with ARBs or ACEIs compared to other AHTs 1 . In a subsequent much larger study, Shaw and colleagues 2 showed that monotherapy with ARBs or ACEIs was associated with lower rates of a first diagnosis of depression compared to other AHTs, with β-blockers being associated with the highest risk. These authors also found that a diagnosis of bipolar disorder was less common with ARBs and ACEIs.…”

Differences in the Microbial Composition of Hemodialysis Patients Treated With and Without β-Blockers

“…However, an enriched Flavonifractor in major depressive disorder [45] and bipolar disorder [46] could also link the relationship between β-blockers and major depressive disorder or bipolar disorder. [49] We also identi ed a potential link between β-blocker use and the genus Tyzzerella in the PS-matched cohort. Importantly, Tyzzerella was enriched in those with a high cardiovascular risk pro le.…”